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BACKGROUND: Endometrial cancer is the most common gynaecological cancer in the western world, the incidence increasing in the
United Kingdom by over 40% since 1993. Two types of endometrial cancer exist – oestrogen-dependent type 1 with good prognosis
and non-oestrogen-dependent type 2 with poor prognosis. The histopathological distribution of the increase in endometrial cancer is
unknown. This study investigates the observed incidence trends of the two types, the age, stage, and socioeconomic distribution of
this increase and survival outcome.
METHODS: Data were analysed from 6867 women with endometrial cancer registered between 1994 and 2006, at a UK population-
based cancer registry.
RESULTS: Increased endometrial cancer incidence is confined to type 1 cancers with a significant increase in age standardised incidence
rate (ASR) from 12.0 per 100000 (confidence interval (CI) 10.7–13.2) in 1994 to 16.3 per 100000 (CI 14.9–17.7), Po0.001 in
2006, while ASR of type 2 cancer changed from 2.5 per 100000 (CI 2.0–3.1) in 1994 to 2.2 per 100000 (CI 1.7–2.7) in 2006, which
was not statistically significant P40.05. Increase in type 1 cancer is most marked in age groups 60–69 years (Po0.001) and 70–79
years (Po0.001) and distributed equally among socioeconomic quintiles. While outcome for type 1 cancer has improved, 1-year
survival in type 2 cancer is unchanged from 73.1% in 1994 to 74.3%, P¼0.089 and 5-year survival decreased from 55.1% to 40.9%,
P¼0.001.
CONCLUSION: Increased incidence in endometrial cancer is confined to type 1 cancers, seen most in the 60–79 age groups and across
all socioeconomic quintiles. Survival in type 2 cancer has decreased significantly. Urgent research is needed to investigate prevention
strategies in type 1 and improve therapy in type 2 cancers.
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Endometrial cancer is now the most common cancer of the female
genital tract in the western world, with an estimated worldwide
incidence of 287000 and 74000 deaths from endometrial cancer in
2008 (Ferlay et al, 2010). Endometrial cancer has increased by over
40% in the United Kingdom since 1993, to 7536 cases in 2007 and
1741 deaths in 2008 (http://info.cancerresearchuk.org/cancerstats/
types/uterus/). While the incidence and mortality rates of several
other cancers have plateaued or decreased in the last decade the
incidence of endometrial cancer has been rising throughout
Europe (Jemal et al, 2008). This increase has been attributed to
increasing obesity, life expectancy, and adjuvant Tamoxifen use for
breast cancer (Bray et al, 2005).
Endometrial cancer can be classified into two distinct groups –
type 1 and type 2 based on histology, which differ in molecular as
well as in clinical and histopathology profiles (Bokhman, 1983).
Type 1 endometrial cancer is oestrogen-driven, of endometrioid
histology, arises in the background of endometrial hyperplasia, is
strongly linked to obesity, occurs predominantly in pre and
perimenopausal women and is associated with good prognosis
(490% 5-year survival rate) (Doll et al, 2008). Type 2 is non-
oestrogen dependent, non-endometrioid, with higher grade
histologies, specifically uterine papillary serous carcinomas
(UPSCs) and clear-cell carcinomas, more aggressive, and carries
an adverse prognosis (Amant et al, 2006; Mendivil et al, 2009).
Although type 2 cancers contribute only 10% of endometrial
cancer incidence, they cause 50% of recurrence and deaths from
endometrial cancer with a low 5-year, all stage, overall survival rate
of 35% (Singh et al, 2008; Bansal et al, 2009). Type 2 cancers
typically arise in an atrophic endometrial background, and often
have deep myometrial penetration and demonstrate lymph node
spread. They usually occur at an older age, B5–10 years later than
type I tumours. In addition, type 1 endometrial carcinomas
are characterised by mutations in PTEN, PIK3CA, KRAS, and
b-catenin, along with microsatellite instability; type 2 endometrial
carcinomas are characterised by genetic alterations in p53, HER-2/
neu, p16, and E-cadherin (Llobet et al, 2009).
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yAlthough the increase in incidence in endometrial cancer is
well recognised, the distribution of this increase across the two
types of endometrial cancer is not known. This information has
vital implications for health policy and the development of
targeted therapies in endometrial cancer. Understanding the
trends in incidence of endometrial cancer and socioeconomic
distributions may help inform strategies to improve early
diagnosis and therapy and target healthcare resource efficiently.
In this study, we present an analysis of the observed incidence
trends of the two major types of endometrial cancer in the West
Midlands area of the United Kingdom from 1994 to 2006. We
sought evidence of a differential increase between type 1 and type 2
cancers over this time period, and whether or not this varied with
socioeconomic distribution. We also explored age and stage
distribution of endometrial cancers over this time period and
survival outcome based on histology type and socioeconomic
deprivation.
METHODS
Population details
Analysis was performed of prospective data collated on all newly
diagnosed endometrial cancer patients registered between 1994
and 2006 at the West Midlands Cancer Intelligence Unit (WMCIU).
Registration of a cancer diagnosis usually occurs within 3 months
of diagnosis, though registration of all clinical information can
take longer. All analysis involving patient identifiable data was
conducted on fully complete cases in house by the researchers
employed by the WMCIU who are authorized to access these
confidential data. The data were then tabulated for use within the
paper. The WMCIU houses a population-based cancer registry
serving the 5.4 million residents in the West Midlands region of
the United Kingdom. All neoplasms of invasive, in situ, uncertain
or unknown behaviour are recorded on the WMCIU’s central
database. The WMCIU aims to register each case from a range of
data sources to ensure the most accurate information possible –
full coding of a cancer case may involve data from hospital patient
information systems, pathology reports, medical records depart-
ments, radiotherapy systems, hospices, other cancer registries,
general practices, private hospitals, cancer screening programmes,
nursing homes, and death certificates.
Histology
The registry records data on the histology of the cancer as
determined by the pathologist issuing the histology report at the
time of diagnosis of cancer. These histology reports were
categorised into the International Statistical Classification of
Diseases and Related Health Problems, 10th Edition, Volume 1
(World Health Organisation) (ICD-10) code C54¼malignant
neoplasm of corpus uteri and code C55¼malignant neoplasm of
uterus, part unspecified. Specific histopathological tumour types
were classified in accordance with the International Statistical
Classification of Diseases and Related Health Problems, 10th
Edition, Volume 3 (World Health Organisation), referring to the
morphology of the cancer site by the same international
classification. These morphologies were then further grouped into
type 1 and type 2 endometrial cancers by the specialist
histopathologist in gynaecological cancer on the team (RG). The
WMCIU researchers then applied the appropriate type, based on
the groupings produced, to the actual cases included within the
study so that the analysis could be carried out.
Type 1 included common indolent types of endometrial
adenocarcinoma, which were coded as grades 1–3 endometrioid,
mucinous, or adenocarcinoma. Type 2 encompassed the more
uncommon and highly aggressive types of uterine cancer. These
included those coded as serous, clear-cell, carcinosarcoma or
malignant mixed mullerian tumour. Uterine sarcomas and other
types of endometrial cancers that are distinct from the above two
subtypes were excluded from analysis (Table 1).
Social deprivation
The Indices of Multiple Deprivation 2004 (IMD 2004) is a
deprivation index at the small area level, created by the British
Department for Communities and Local Government. Commisi-
soned and published by the Department for Communities and
Local Government, the Indices of Deprivation 2004 are based upon
a mix of 2001 national census data and 2001 administrative data
sources. These have been updated with more recent (2005)
administrative data sources from Government Departments and
have been published as Indices of Deprivation 2007 (Department
for Communities and Local Government TEIoDoL). IMD 2004 is
made up of seven distinct dimensions of deprivation called domain
indices, which relate to deprivation in income, employment, health
and disability, education skills and training deprivation, barriers to
housing and services, living environment deprivation, and crime.
The deprivation score of the area where the individual lives is
assumed to be characteristic of the deprivation experienced by all
individuals living there. Scores are calculated at small geographical
areas (lower super output areas (LSOA), each containing B1500
people), but there may still be some variation in deprivation within
each LSOA which is not captured in this analysis. All LSOAs in
England were ranked according to their deprivation (measured by
the 2004 income domain score) and divided into five equal groups
(quintiles). The top 20% was defined as the ‘most affluent
population of England’. All LSOAs in the West Midlands that
were within the scores for the ‘most affluent population of
England’ were defined as ‘the most affluent population’ in the West
Midlands, and conversely LSOAs that were within the scores for
‘the least affluent population of England’ were defined as the ‘least
affluent population’ in the West Midlands. Each cancer registration
is routinely assigned a deprivation score and quintile by the
WMCIU based upon the diagnosis postcode/address information
received for each case. The data for this study therefore already
contain the deprivation index. Because of the possibility of
‘mathematical coupling’ whereby the relationship between IMD
2004 and markers of health can be predicated by including the
health domain of IMD 2004, this analysis focuses only on the
income domain of IMD 2004 where 1¼the most deprived and
5¼the least deprived (Archie, 1981; SIGN, 2002).
Statistical analysis
Age standardised incidence rates (ASRs) were calculated via the
direct method. Age standardisation was conducted using the
standard European population throughout; all figures are based on
a female population. To assess the statistical significance of the
results, 95% confidence intervals (CIs) were also calculated for the
ASRs using the Poisson distribution (Breslow NEaDNE, 1987).
Relative survival analysis was performed to calculate survival rates.
Relative survival is defined as the observed survival in the patient
group divided by the expected survival of the general population,
matched by age, sex, and calendar year (Dickman et al, 2004).
Relative survival was calculated in STATA (v.11) (StataCorp LP,
College Station, TX, USA) using the strs programme which
calculates relative survival estimates using the Ederer II method
(Evaluation Section NCI, 1959; http://www.pauldickman.com/
survival/strs.pdf). National life tables were obtained from the
Cancer Research UK Cancer Survival Group at the London School
of Hygiene and Tropical Medicine. One- and five-year relative
survival was calculated using 5 year rolling averages.
The incidence of endometrial cancer, its two subtypes, and the
relative proportions were tested with Pearson’s correlation with
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socioeconomic class, we pooled data from classes 1 and 2, and
classes 4 and 5 for improved power. This therefore gives two
groups of approximately equal sample size. We did not analyse
data from class 3 as it lacks the power for a rigorous analysis.
P-value of 0.05 was considered significant.
RESULTS
A total of 7465 women with endometrial cancer were registered at
the WMCIU during 1994–2006. We excluded 598 cases that did
not conform to either type 1 or type 2 histology, giving a final total
of 6867 cases. Of these, 5903 were classified as type 1 and 964 as
type 2 endometrial cancers as per histology classified in Table 1.
The proportion of excluded morphologies remained fairly constant
over time, with, on average 8% excluded between 1994 and 2006
(Table 1). Less than 2% of endometrial cancers analysed as type 1
or type 2 and utilised for this analysis were death certificate only
(DCO) registrations. These cases have been included for the
purpose of calculating incidence rates as they represent real cases
and so trends in incidence of these endometrial cancers were
analysed. Given that DCOs represent o2% of cases, they have been
removed from the survival analysis due to insufficient information
regarding the duration of disease and the possible bias this could
introduce to the analysis. This is a widely used approach applied in
other studies of cancer survival (De Angelis et al, 2009; Coleman
et al, 2011).
An overall increase in the ASR of endometrial cancer was
observed over the time period, from 16.1 per 100000 population
(CI 14.6–17.5) in 1994 to 19.6 per 100000 population (CI 18.1–21.1)
in 2006. Analysis by type of endometrial cancer revealed a marked
differential trend in incidence by type. The ASRs of type 1 cancers
showed a highly significant linear increase from 12.0 per 100000
(CI 10.7–13.2) in 1994 to 16.3 (CI 14.9–17.7) in 2006, r¼0.94,
Po0.001. However, the ASR of type 2 cancers remained static; 2.5
per 100000 (CI 2.0–3.1) in 1993 compared with 2.2 per 100000 (CI
1.7–2.7) in 2006, r¼ 0.15, P-value¼0.633. This is represented
graphically in Figure 1.
The overall distribution of our cases among the socioeconomic
quintiles was roughly similar with the exception of the smaller
proportion of cases overall that were diagnosed in the most
Table 1 Classification of endometrial cancer into types 1 and 2 and histology excluded from analysis
Type 1 Type 2 Excluded histologies
Adenocarcinoma NOS (ICD10, C54 & C55) Adenocarcinoma with neuroendocrine differentiation
(ICD10, C54)
Adenocarcinoma with mixed subtypes (ICD10, C54)
Adenosquamous carcinoma (ICD10, C54 & C55) Carcinoma, anaplastic NOS (ICD10, C54 & C55) Adenocarcinoma with squamous metaplasia
(ICD10, C54 & C55)
Carcinoma NOS (ICD10, C54 & C55) Carcinoma, undifferentiated NOS (ICD10, C54 & C55) Adenocarcinoma, metastatic NOS
(ICD10, C54 & C55)
Endometrioid adenocarcinoma (ICD10, C54 & C55) Carcinosarcoma NOS (ICD10, C54 & C55) Adenoid SCC (ICD10, C55)
Endometrioid adenocarcinoma, ciliated cell variant
(ICD10, C54)
Clear-cell adenocarcinoma NOS (ICD10, C54 & C55) Acantholytic SCC (ICD10, C55)
Mucin producing adenocarcinoma (ICD10, C54) Mesodermal mixed tumour (ICD10, C54 & C55) Adenosarcoma (ICD10, C54 & C55)
Mucinous, mucoid adenocarcinoma (ICD10, C54) Mullerian mixed tumour (ICD10, C54 & C55) Carcinoma, metastatic NOS (ICD10, C54 & C55)
Papillary adenocarcinoma NOS (ICD10, C54) Choriocarcinoma NOS (ICD10, C55)
Papillary carcinoma NOS (ICD10, C54) Endometrial stromal sarcoma (ICD10, C54 & C55)
Papillary cystadenocarcinoma NOS (ICD10, C54) Epithelioid leiomyosarcoma (ICD10, C54 & C55)
Papillary serous cystadenocarcinoma (ICD10, C54) Leiomyosarcoma NOS (ICD10, C54 & C55)
Serous cystadenocarcinoma NOS (ICD10, C54 & C55) Mesenchymoma, malignant (ICD10, C55)
Serous surface papillary carcinoma (ICD10, C54) Mixed cell adenocarcinoma (ICD10, C54)
Neoplasm, malignant (ICD10, C54 & C55)
Neoplasm, metastatic (ICD10, C55)
Pseudoglandular SCC (ICD10, C55)
Rhabdomyosarcoma NOS (ICD10, C54)
Sarcoma NOS (ICD10, C54 & C55)
Sarcomatosis NOS (ICD10, C55)
Signet ring cell carcinoma (ICD10, C54)
Solid carcinoma NOS (ICD10, C55)
Spindle cell carcinoma (ICD10, C54 & C55)
Spindle cell sarcoma (ICD10, C55)
Squamous cell carcinoma NOS (ICD10, C54 & C55)
Stromal sarcoma, NOS (ICD10, C54 & C55)
Teratoma, malignant NOS (ICD10, C54)
Transitional cell carcinoma NOS (ICD10, C54)
Tumour cells, malignant (ICD10, C54)
Abbreviations: ICD¼International Classification of Disease; NOS¼not otherwise specified; SCC¼squamous cell carcinoma.
Note that this table only accounts for the tumours registered on the West Midlands Cancer Intelligence Unit (WMCIU) database, therefore where morphologies have only been
assigned to a single ICD10 cancer code, this reflects the WMCIU database and does not necessarily mean that morphology is only diagnosed in that ICD10 cancer site.
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Figure 1 Differential trends in endometrial cancer incidence across the
two types. Age standardised incidence rates and confidence intervals are
shown.
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yaffluent quintile (Table 2; quintiles 1–5 with 1 being most deprived
and 5 being least deprived). Analysis of the increase in type 1
endometrial cancer by socioeconomic distribution revealed that
this increase in incidence rates was evenly distributed among all
socioeconomic quintiles. There was a strong relationship between
the rates of increase in groups 1 and 2 vs groups 4 and 5, r¼0.74,
P¼0.004. Figure 2 represents an analysis of type 1 cancer
incidence comparing groups 1 and 2 with groups 4 and 5. When
analysing the distribution of all cases by age, the largest proportion
of cases fell in the 60–69 age group, which accounted for 31% of all
cases. The 0–59 group was the second largest, although in over
99% of cases, the age at diagnosis was in the 30–59 age group
(Table 3). To investigate the impact of increased life expectancy on
type 1 cancer we analysed the ASRs in age groups 0–59, 60–69,
70–79, and over 80 years. An increase in type 1 endometrial cancer
was seen in age groups, 0–59 years: r¼0.707, P¼0.007; 60–69
years: r¼0.861, Po0.001; and 70–79 years: r¼0.838, Po0.001
over the study period, while the age standardised incidence in the
over 80 years remained static; 80þ years: r¼0.24, P¼0.418
(Figure 3).
Over the study period, there was an overall improvement in 1-year
and 5-year relative survival rates for all morphologies combined
(types 1 and 2 and all other morphologies) of endometrial cancer.
One-year survival improved from 85.6% in time period 1994–1998
to 90.3% by 2003–2007, and 5-year survival from 73.2% in 1994–
1998 to 75.8% in 1999–2003, r¼0.86, P¼0.001. This improvement
was limited to type 1 cancer, with 1-year survival improving from
89.1% in 1994–1998 to 94.7% by 2003–2007, r¼0.94, Po0.001.
Five-year survival in type 1 cancer increased slightly from 78.7% to
82.4%, r¼0.33, P¼0.950, but the difference was not statistically
significant. Specifically, outcome for type 2 cancers demonstrated a
deterioration over time, with 1-year relative survival unchanged from
73.1% in 1994 to 74.3%, r¼ 0.56, P¼0.089 and 5-year relative
survival decreasing from 55.1% to 40.9%, r¼ 0.98, P¼0.001 over
the study period (Figure 4).
We investigated survival by individual deprivation quintile and
by separate subtype, however, due to small numbers, the data were
found to lack robustness and so have not been presented. To
investigate the deprivation gap in relative survival for endometrial
cancer we therefore combined all morphologies (type 1, type 2 and
all other morphologies). One-year survival rates for endometrial
cancer showed no impact as a result of deprivation, 2003–2007
data, groups 1 and 2 showed 90.5% (CI 88.4–92.2%) while groups
4 and 5 showed 90.0% (CI 87.9–91.7%) relative survival rates.
However, analysis of 5-year survival in women diagnosed from
time periods 1994 to 2003, demonstrated a significant improve-
ment in relative survival in more affluent groups 4–5, from 74.8%
to 78.5%, r¼0.66, P¼0.036, while survival was not significantly
better, 69.8–72.4%, r¼0.66, P¼0.151 in less affluent groups 1–2,
over the study period. The difference in survival between groups
1–2 and 4–5 was not significant, r¼0.27, P¼0.6. Type 1 cancer
was more frequently diagnosed at an earlier stage, 69% at stages 1
Table 2 Socioeconomic distribution of endometrial cancers diagnosed in
the West Midlands, 1994–2006
Deprivation quintile Proportion (%)
Least affluent 21.1
Less affluent 20.7
Average 20.4
More affluent 22.6
Most affluent 15.1
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Figure 2 Analysis of increase in type 1 endometrial cancer rates by
socioeconomic distribution. Confidence intervals for both graphs overlap at
each time point.
Table 3 Age distribution of endometrial cancers diagnosed in the West
Midlands, 1994–2006
Age group (years) Proportion (%)
0–29 0.1
30–34 0.3
35–39 0.9
40–44 1.7
45–49 3.8
50–54 8.8
55–59 14.2
60–64 15.2
65–69 15.3
70–74 13.5
75–79 12.0
80–84 7.7
85+ 6.3
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Figure 3 Analysis of type 1 endometrial cancer incidence by age groups.
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Figure 4 Five-year relative survival of endometrial cancer types 1 and 2.
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data have to be interpreted with caution, as data on stage were
incomplete in at least 20% of cases.
DISCUSSION
This study identifies a differential increase in endometrial cancer
from 1994 to 2006 based on data from a population-based cancer
registry, with a marked increase in oestrogen-dependent type 1
cancers and a static level of type 2 cancers. To our knowledge, this is
the first paper to demonstrate this differential increase. Investigation
of ASRs in the different age groups revealed an increase across most
age groups 0–79 years, most markedly in age groups 60–69 and
70–79 years. Our data demonstrate the likelihood of an enduring
type 1 endometrial cancer risk from hyper-oestrogenic states that
persists well beyond the perimenopausal time frame. There is a need
for research in prevention strategies that can target this persistent
risk, for example, long-term prophylaxis with progesterone or the
Mirena progesterone coil, particularly in those most at risk.
Increasing body mass index shows a strong linear relationship with
endometrial cancer and some postulate that the incidence of
endometrial cancer will rise to twice the 2005 rates by 2015 (Bjorge
et al, 2007; Reeves et al, 2007; Renehan et al, 2008; Lindemann et al,
2008, 2010). In the affluent developed world, obesity is unevenly
distributed with greater prevalence in the more deprived socio-
economic groups (Friel et al, 2007). The prevalence of obesity in
women has been shown to rise steadily and significantly with
increasing area deprivation from 20.1% in the least deprived to 33.1%
in the most deprived (http://www.scotpho.org.uk/home/Clinicalrisk-
factors/Obesity/obesity_data/obesity_deprivation.asp). Given that
obesity is a significant main driver for oestrogen-related endometrial
cancer incidence, we investigated if a difference in incidence within
socioeconomic quintiles could be shown. Interestingly, we did not
find any difference in distribution among the quintiles with no
difference between quintiles 1–2 and quintiles 4–5 and this has
remained so over the 12 years in the study period. Our findings are
consistent with national data in endometrial cancer and suggest that
the relationship between endometrial cancer incidence, obesity, and
deprivation is complex (Cooper et al, 2008).
The significant deterioration in 5-year survival rates for type 2
cancers, while incidence remains static, may reflect greater awareness
of pathologists of these histologies and improved pathological
classification. Our findings are consistent with the Surveillance,
Epidemiology and End Results database (SEER), United States study
of 445000 women with endometrial cancer, which suggest that there
is an increase in mortality which may be related to advanced-stage
cancers and high-risk histologies namely UPSC and clear-cell
carcinoma (Ueda et al, 2008). A significant deprivation gap in
survival exists between the most affluent and the most deprived
groups with endometrial cancer of B4% based on data from England
and Wales with survival lagging 2–6% behind Europe (Kitchener,
2008). Our study confirms that recent improvements in 5-year
survival are seen mostly in the more affluent groups, showing that
more work is needed to overcome this discrepancy.
The strengths of the study are that it is population based, with data
subjected to robust quality assurance and, and is therefore likely to
accurately reflect changes in incidence in a broader population.
This methodology of using a high resolution look at population-based
cancer registry data captures trends and significant findings and has
been validated previously (Gatta et al, 2010). Some caveats with this
study’s findings must be noted. The West Midlands is a diverse
region of the United Kingdom, comprising 9% of the population of
the United Kingdom with wide variation between urban inner city
areas and large rural areas. The region has a higher multiethnic
population, 11.3% comprising ethnic minorities. The largest ethnic
minority community is Indian (3.4%), followed by Pakistani (2.9%)
and Black Caribbean (1.9%) (http://www.statistics.gov.uk/census2001/
profiles/commentaries/west_midlands.asp#Population, National Sta-
tistics, 2001). This population profile may impact on our results. We
were unable to investigate ethnicity data and relationship with
endometrial incidence, as the classification of ethnicity changed
during the study period preventing robust analysis. However, given
that the mortality and age profiles of the West Midlands are similar to
the rest of the United Kingdom, we believe the results are valid and
are likely to reflect profiles of endometrial cancer in the broader
population. Because of small numbers, we were also unable to assess
any differences in survival for type 1 and type 2 endometrial cancers
by socioeconomic group. With data from only one cancer registry,
t h ec o n f i d e n c ei n t e r v a l sa r eq u i t el a r g ea n dr e p e a t i n gt h i sh i g h
resolution analysis with data from a number of registries may yield
greater insight and enable further analysis. While some cases of type 2
endometrial cancer specimens during 1994–2006 were sent to the
regional gynaecological cancer centre for central pathology review by
a histopathologist specialising in gynaecological cancers this was not
uniform and a further study with expert review of pathology may add
greater insight. However, given that the percentage of type 2 cancers
has remained static over the time period, we believe that the influence
of expert pathology on classification of these tumours is unlikely to
impact significantly on the incidence trend observed. Since the study
period, there has been greater centralisation of gynaecological
oncology services and the impact of this on survival will need to be
assessed in future studies.
CONCLUSION
Our study shows that the increase in incidence in endometrial
cancer is confined to type 1 endometrial cancer, while type 2
cancer has remained static over the 12-year study period. This
increase is seen across all deprivation quintiles and all age groups
except the over 80 years. The most significant increases are seen in
the 60–79 age groups, suggesting that the oestrogenic impetus for
developing type 1 endometrial cancer extends well beyond the
perimenopausal years. Survival in type 2 cancers remains poor and
has deteriorated. Urgent research into prevention strategies for
type 1 endometrial cancer and the role of targeted therapies in type
2 cancer is needed. Research is also needed to improve early
diagnosis by public health education and better referral pathways.
These may improve outcome in the more deprived groups.
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